206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)

Background

WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from pts diagnosed with a solid tumour profiled with NGS. The goal is to advance precision medicine by providing high-quality real-world data (RWD) to researchers internationally.

Methods

WAYFIND-R data are electronically collected into a centralised database with standardised forms and high quality data management procedures. To ensure reliability/accuracy and a fit-for-purpose data source, data are periodically evaluated. Enrolment began in Sep 2020. Sites submit baseline pt, tumour, biomarker, NGS and molecular tumour board (MTB) decision making at enrolment, and treatment and outcome data at routine follow up.

Results

As of 31 Mar 2023, 855 pts had complete baseline data collection and cancer-related information; 755 carried on to the next data collection, 119 had died and 18 had ended participation. Pts were enrolled at 61 sites across 23 countries, mostly at academic institutions/university hospitals. The median age was 65 years (range: 20–93), 50% were female, 49% were retired and 62% had government insurance. WAYFIND-R had 109 cancer types and 160 subtypes (most common: adenocarcinoma [n = 389]). The most commonly detected genes were TP53, KRAS, EGFR, BRAF and APC. The most commonly screened non-NGS biomarkers were cytokeratin 7 (CK7/KRT7), PD-L1, CA19-9, CEA and Ki67. Table shows data for the most common cancer types in the registry.Many pts (n [ 341; 40%) had not been evaluated by an MTB. The most frequent MTB recommendation after NGS testing (n [213; 25%) was to start other treatment (chemotherapy: 63%; immunotherapy: 19%; targeted therapies: 18%). Table: 206P

Conclusions

The WAYFIND-R registry captures precision oncology data using a standardised approach globally. WAYFIND-R can enable further insights into clinical decision making, the timeliness of NGS testing and access to therapy.

Clinical trial identification

NCT04529122, first posted 27 August, 2020.

Editorial acknowledgement

Research support for third-party writing assistance for this abstract, furnished by Eleanor Porteous, MSc, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

J. Blay: Financial Interests, Personal, Advisory Board: Bayer, Deciphera, GSK, Roche; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Institutional, Invited Speaker: MSD, MSD; Financial Interests, Personal, Other, member of the supervisory board: Innate pharma; Financial Interests, Institutional, Funding: MSD, BMS, Deciphera; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bayer, GSK, Novartis, OSE pharma. A. Hackshaw: Financial Interests, Personal, Stocks/Shares: Illumina, Thermo Fisher; Financial Interests, Institutional, Research Grant: F. Hoffmann-La Roche Ltd., MSD Oncology, Takeda, BMS, Boehringer Ingelheim , Celgene; Financial Interests, Personal, Other, Honoraria: AbbVie, Boehringer Ingelheim, Takeda, AstraZeneca, Daiichi Sankyo, Merck Serono, Merck/MSD, USB, F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Advisory Role: AbbVie, F. Hoffmann-La Roche Ltd, Grail, Inc.; Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. C. Le Tourneau: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck Serono, Nanobiotix, Roche, Rakuten, Seattle Genetics, GSK, Celgene, ALX Oncology, Exscientia. J. Geissler: Financial Interests, Institutional, Research Grant: Novartis, Incyte, Bristol Myers Squibb, Pfizer, Takeda; Financial Interests, Personal, Other, Travel: Amgen, Alnylam, BioMarin, Novartis, Pfizer, Roche, Servier, UCB; Non-Financial Interests, Personal, Advisory Role: Alnylam, Bayer, Boehringer Ingelheim, BioMarin, Daiichi Sankyo, Gilead, Janssen, Novartis, Pfizer, Roche, Servier, Sanofi, Sobi, UCB; Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. A. Ferro: Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: Roche Products Limited; Non-Financial Interests, Personal, Other, Research funding: Support for third-party editing assistance from F. Hoffmann-La Roche Ltd.: F. Hoffmann-La Roche Ltd. E. Schirgruber: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd.: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd. O. Skatkova: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd.: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd. R. Dienstmann: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, Ipsen, Libbs, Lilly, Merck Sharp & Dohme, Roche, Sanofi, Servier, GSK, Takeda, Janssen, Foundation Medicine; Financial Interests, Personal, Advisory Board: Bayer, Roche; Financial Interests, Personal, Full or part-time Employment, Oncoclínicas is a private healthcare provider in Brazil. I work part time as Medical Director of the Precision Medicine and Big Data Initiative. We develop molecular tests (pathology and genomics) that are offered to patients treated in the organisation as part of support programs sponsored by pharmaceutical companies and I coordinate research activities with real-world clinico-genomics cohorts.: Oncoclínicas; Financial Interests, Personal, Stocks/Shares: Trialing; Financial Interests, Personal, Research Grant: Merck.